Cereno Scientific’s drug candidate CS585 highlighted by top-tier medical journal Blood as a promising novel anti-thrombotic strategy without risk of bleeding
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the recently published paper on CS585 in the top peer-reviewed medical journal Blood was selected to feature in the journal’s Blood Podcast as well as awarded a commentary titled “Targeting prostacyclin: all gain with no pain?” concluding that the discoveries reported by Stanger and colleagues mark an important milestone to improve anti-thrombotic strategies.The article published in Blood shows that CS585, a prostacyclin receptor agonist,